anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation method for a traditional Chinese medicine lotion for treatment of hypertension-type closed fractures,and belongs to the technical field of traditional Chinese medicine preparation methods. At present, treatment of hypertension-type closed fractures generally uses western medicines. A disadvantage of using western medicines is that certain side effects exist. The technical solution of the invention includes: taking radix achyranthis bidentatae, hematite, white silkworm, trillim tschonskii maxim, scorpio, cassia seed, oyster shell, puncturevine caltrop fruit, apocynum venetum, hawksbill carapace, mother-of-pearl, gambir plant, rauwolfia, earthworm, snake slough, cowrie shell, centipedec, dung beetle, hedge prinsepia nut, pummelo fruit, flos caryophyllata, fruit of fiverleaf akebia, fructus anisi stellati, common jasminorange, aspongopus, sword bean, elecampane inula root, szechwan chinaberry fruit, decapetalous caesalpinia, combined spicebush root, sandalwood, and liquorice root; soaking the above 32 traditional Chinese medicines in water; decocting by slow fire; and filtering to remove dregs. The left medicine liquid is the traditional Chinese medicine lotion for the treatment of hypertension-type closed fractures. The lotion has the advantages that the traditional Chinese medicine liquid is fewer in side effects, short in treatment courses, and high in cure rate.
329,305. Sandqvist, H., and Lindstr÷m, T. O. H. Feb. 14, 1929. Emulsions, making; ointments or salves.- Petroleum jelly, paraffin, lubricating oils, fatty oils and other substances of a fatty or oily nature are combined, preferably during heating, with 0.1-10 per cent of one or more phytosterins to form compositions capable of absorbing water, water solutions or substances such as glycerine, the absorbed substance being dispersed in the base. The products are applicable to the manufacture of ointments, medical and cosmetic salves, lubricants, paints, and food-products such as margarine. The phytosterins may be oxidized before addition or air may be passed through the liquified base during the addition in order to oxidize the phytosterins in situ. Examples refer to the addition of 3 per cent of a phytosterin to petroleum jelly, paraffin or lubricating oil, the mixture being heated, if desired, to 180‹-200‹C while stirring and passing air therethrough. The products are capable of absorbing two to three times their weight of water or water-solutions of substances such as glycerine, aluminium subacetate, silver nitrate or iodine. Petroleum jelly containing 50 per cent of a phytosterin is stated to be capable of absorbing four times its weight of water; in place of water, glycerine, aqueous alcohol or other substances may be absorbed. The preparation of salve bases, capable of absorbing water, water solutions or other liquids, by the addition to petroleum jelly, paraffin &c. of oxycholestrin or oleic acid is referred to.
The study is designed as a prospective, open, randomized controlled trial involving patients aged 18-28 years of both genders with uni- or bilateral keratoconus planned for routine corneal crosslinking at the Department of Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study involves 30+30 eyes with keratoconus, which are randomized to receive either conventional corneal crosslinking (n=30) using the Dresden protocol or a modified treatment - corneal reshaping and crosslinking (n=30), where a rigid contact lens is sutured to the cornea during the treatment to flatten the corneal curvature and potentially improve the optical outcome after the treatment. Patients are randomized utilizing a list of unique random numbers between 1 and 60. All patients are informed about the procedures before consenting to participate in the study. The study also involves 60 eyes of healthy age- and sex-matched control subjects.

At baseline, before treatment, each eye is evaluated with autorefractometer measurement, best spectacle-corrected LogMAR visual acuity, Pentacam Scheimpflug photography, Goldmann applanation tonometry and biomicroscopy. The corneal biomechanical characteristics are assessed with applanation resonance tonometry and the ocular response analyzer. The investigations are repeated at 1 month, 6 months, 2 years and 5 years after the treatment.
This is a prospective, randomized, double-blind study. Subjects who have completed the 6-month Treatment Period in 18-OBE2109-002 - Edelweiss 2 study (herein referred to as main study) will be invited to enter the present extension study. Month 6 visit of the main study is a decision point for Subjects to either end treatment and enter a post-treatment follow up (part of the main study), or to opt for a 6-month treatment extension. All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or 200 mg combined with ABT for 6 months. Subjects who received placebo during the main study will be randomized to either linzagolix 75 mg alone (with ABT placebo) or linzagolix 200 mg with ABT. Subjects who received active treatment during the main study will continue with the same treatment. Double-dummy design will be used in order to maintain the blinding of the study.

After end of treatment in the extension study (6-month treatment period: from Month 6 to Month 12), subjects will enter a post-treatment Follow-Up Period of 6 months with no investigational medicinal product (IMP) or - for subjects willing to continue treatment - a second extension study will be proposed.
With over 10 million individuals infected worldwide, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health crisis. It is recognized that pregnant women are at an increased risk of acquiring viral respiratory infection and developing severe pneumonia due to the physiologic changes in their immune and cardiopulmonary systems. Previous studies have attempted to determine maternal and perinatal outcome and potential risk of vertical transmission in pregnant women affected by COVID-19, however, relevant clinical data and biological samples have not been collected in a systematic manner. The research project will engage in collaborative research across obstetricians/maternal-fetal medicine subspecialists, gynecologist, infectious disease specialists, pediatrician, developmental and molecular biologists and bioinformatician between the CUHK, China and Spain. The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.

Results generated will inform obstetrics and gynecology, pediatric and infectious disease scientific communities as well as public health specialists and policy makers regarding: (1) the estimated seroconversion rate in women of childbearing age; these results will help (i) improve the approach to care for pregnancy and childbirth during the COVID-19 outbreak; and (ii) formulate preventive measures to be implemented specifically for pregnant women in reducing risk of infection and associated complications to both the women and their unborn child; (2) the impact of COVID-19 on maternal and perinatal outcomes; data from high-quality research will inform practice during the COVID-19 outbreak, guiding healthcare professionals on how to adjust the management approach to infected pregnant women and the exact risks the infection poses to the babies; (3) the risk of vertical transmission at different stages of pregnancy and its sequelae; findings of this study will guide counselling, decision making and clinical management; (4) the identification of cellular site of viral entry and replication in the maternal-fetal interface that would be instrumental in designing therapeutic measures to cease vertical transmission and developing therapeutic treatments.
This was a Phase 3 multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the inhibition of radiographic progression by adalimumab compared with placebo in adult Japanese patients with early rheumatoid arthritis (RA) who had not been previously treated with methotrexate (MTX). Eligible participants were randomized 1:1 to receive either a subcutaneous injection of adalimumab 40 mg or matching placebo every other week (eow) during the 26-week double-blind phase. All participants also received 6 mg to 8 mg MTX weekly as basal treatment for their disease. Participants who experienced an increase in disease activity (more than 20% increase in tender joint count and swollen joint count) at Week 12, 16, or 20 compared with Baseline after having increased MTX dose to 8 mg per week for at least 4 weeks were discontinued from the double-blind phase and were eligible to receive open-label adalimumab 40 mg eow as rescue treatment. Participants who completed the 26 weeks of treatment (either double-blind study drug \[adalimumab or placebo\] treatment or open-label adalimumab treatment) were eligible to enter the 26-week open-label phase in which they received adalimumab 40 mg eow. Efficacy and safety assessments were performed at Baseline and at designated study visits.
The invention concerns antiseptic ointments for external application comprising, as a basis, pharmaceutical Vaseline or a mix of pharmaceutical Vaseline with lanoline, and, as the antiseptic agent, a dispersed bentonite powder intercalated by one or more metal ions selected in the group consisting of Ag + , Cu 2+ , Zn 2+ . In addition the ointment contains an etheric vegetable oil. More precisely the active antiseptic agent may be: a dispersed bentonite powder intercalated by ions of Ag +  or by ions of Cu 2+  or by a mix of said bentonites. According to an anternative the antiseptic dispersed bentonite powder may be intercalated by ions of Ag +  and Zn 2+  or by ions of Cu 2+  and Zn 2+  or by ions of Ag + , Cu +  and Zn + . In any case the total content of metals in the composition of ointment is comprised between 0.05-0.5%. The ointments according to the invention are biologically compatible with various integuments of humans and animals and provide a prolonged antiseptic action at low expenses.
PURPOSE: To obtain a Pharmaceutical preparation containing, as active ingredient, a sulfated polysaccharide, usable more safely for nephropathy and having significantly excellent efficacy on the disease. CONSTITUTION: This pharmaceutical preparation contains, as active ingredient, a sulfated polysaccharide (pref. sulfated hyaluronic acid). The sulfated hyaluronic acid is obtained, for example, by sulfating hyaluronic acid derived from e.g. the connective tissue of mammals. The sulfation is conducted, in general, at 50-60 deg.C for several tens hours to several days. The final sulfation rate is normally 50-60% per genuine hydroxyl group of the hyaluronic: acid. When sulfated hyaluronic acid is to be prepared as an injection, it is preferable that its concentration be brought to 0.05-1w/v% in a physiological saline. The dose of the sulfated hyaluronic acid is pref. 0.1-10mg/kg b.w. for an intravenous injection.
FIELD: biology, immunology. SUBSTANCE: method involves incorporation of DNA-sequences encoding light and heavy chains of complete antigen and free of foreign bacterial sequences to the male pronucleus of the fertilized pig ovicell. Then ovicell is implanted in pig female oviduct and progeny is grown. Method is used for preparing diagnostic and prophylactic preparations based on antibodies. EFFECT: improved method of preparing. 1 dwg
Method: Fifty schizophrenic patients who regularly receive outpatient treatment at Sinop Community Mental Health Center will form the universe of the study. Individuals over the age of 18 who have schizophrenia, do not have mental retardation, have no comprehension and hearing problems, have insight, and are in remission will be included in the study. Individuals who meet the study criteria will be divided into experimental and control groups as 22 experimental and 22 control groups. The emotion recognition and expression program prepared by the researchers in line with the literature will be applied to the experimental group for 8 weeks. Personal Information Form, Expression of Emotions Scale, Positive and Negative Syndrome Scale and Toronto Alexithymia Scale were planned to be applied to the experimental and control groups in the pre-test, post-test and follow-up. Follow-up will take place one month after the last session of the study. Psychosocial interventions applied to patients with schizophrenia help patients to increase their level of well-being and quality of life, to decrease negative and positive symptoms by increasing social functionality, to participate in social life, to be an autonomous individual and to prevent stigma. In line with psychosocial interventions, it is thought that the this program to be applied to the patients in this study will basically contribute to the individual patients' ability to recognize their emotions, discuss their emotions, regulate their emotion intensities, and express their emotions. Due to the impact that this program will have on the individual, it is believed that it will have positive results not only for schizophrenia patients, but also for the individuals with whom the patients interact, their relatives and even the society.
The MI experimental group will receive the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 6-month period. MI is an evidence-based communication approach for various health behavior change.
A pharmaceutical composition for treatment of psoriasis is a mixture of garlic (Allium sativum) and seeds of the radish plant (Raphanus sativus) in dilute acetic acid, preferably in the form of white wine vinegar, which is pulverized and blended into a paste. For maximum potency, the composition is preferably prepared immediately before use from fresh ingredients in an amount sufficient for a single treatment. Alternatively, the composition may be prepared ahead of time and stored in a sealed, refrigerated container or otherwise preserved. In the method of treatment, the paste-like composition is applied topically directly to psoriatic plaques on the patient. The composition is allowed to dry on the patient's skin and is left in place for a period of approximately 24 to 72 hours, after which the composition is washed off. The composition is repeatedly applied at intervals of approximately one week over a three to six week period until the desired results are obtained. Typically, the patient's skin will begin to show signs of improvement after the first application of the composition and, after the course of the treatment, the plaque-like lesions will be replaced by healthy, normal skin. The method of treatment is effective on new cases of psoriasis and on long-standing intractable cases of psoriasis, which have not responded to other methods of treatment. Longterm follow-up of patients has shown relatively complete remission of the disease and restoration of normal skin growth for extended periods without recurring symptoms.
PURPOSE:To provide the titled vaccine having extremely excellent activity and high safety, by adding the cell, etc. of Bordetella bronchiseptica to an inactivated antigen obtained by infecting a host animal with various pathogen. CONSTITUTION:A host animal is infected with various pathogen (e.g. Babesia gibsonii of dog, Theileria sergentii of cattle, etc.) and the protozoa are collected at the extreme stage of the proliferation of the protozoa in the body. The protozoa are inactivated with an agent (e.g. formalin, beta-propiolactone, etc.), ultraviolet ray, radioactive radiation, etc. to obtain an inactivated antigen. The antigen is added with the cells of Bordetella bronchiseptica or an oil adjuvant containing the cell component to disperse and emulsify the antigen in the oil. The obtained emulsion is further dispersed and emulsified in a phosphate-buffered physiological saline water containing an emulsifier to obtain the objective vaccine in the form of a W/O/W emulsion.
Personalized treatment strategies based on non-invasive biomarkers have potential to improve patient management in patients with newly diagnosed glioblastoma (GBM). The residual tumour burden after surgery in GBM patients is a prognostic imaging biomarker. However, in clinical patient management, its assessment is a manual and time-consuming process that is at risk of inter-rater variability. Furthermore, the prediction of patient outcome prior to radiotherapy may identify patient subgroups that could benefit from escalated radiotherapy doses. Therefore, in this study, we investigate the capabilities of traditional radiomics and 3D convolutional neural networks for automatic detection of the residual tumour status and to prognosticate time-to-recurrence (TTR) and overall survival (OS) in GBM using postoperative [11C] methionine positron emission tomography (MET-PET) and gadolinium-enhanced T1-w magnetic resonance imaging (MRI). On the independent test data, the 3D-DenseNet model based on MET-PET achieved the best performance for residual tumour detection, while the logistic regression model with conventional radiomics features performed best for T1c-w MRI (AUC: MET-PET 0.95, T1c-w MRI 0.78). For the prognosis of TTR and OS, the 3D-DenseNet model based on MET-PET integrated with age and MGMT status achieved the best performance (Concordance-Index: TTR 0.68, OS 0.65). In conclusion, we showed that both deep-learning and conventional radiomics have potential value for supporting image-based assessment and prognosis in GBM. After prospective validation, these models may be considered for treatment personalization.
BACKGROUND: The perioperative administration of low-dose ketamine has shown potential in postoperative pain management, opioid sparing, and enhancing pain control. This study aimed to investigate the impact of low-dose ketamine on processed electroencephalography (EEG) signals during anesthesia.
METHODS: Forty patients with American Society of Anesthesiologists physical status I-II undergoing elective gynecological surgery were enrolled. EEG monitoring was initiated upon induction of anesthesia. Anesthesia was maintained with desflurane and alfentanil immediately after induction. Fifteen minutes after induction, the ketamine group received a 0.3 mg/kg bolus followed by 0.05 mg/kg/h infusion until completion of surgery. The control group received equivalent saline. Postoperative assessments included pain score (visual analog scale), morphine usage, and quality of recovery.
RESULTS: The ketamine group had significantly higher Patient State Index (PSi) values at 10, 20, and 30 minutes after ketamine administration compared to the controls. Ketamine administration led to significant alterations in EEG patterns, including reduced relative power in delta and theta frequency bands, and increased relative power in beta and gamma frequency bands at 10 minutes post-administration. Relative power in the alpha frequency band significantly decreased at 10, 20, and 30 minutes post-administration. However, there were no differences in intraoperative alfentanil consumption, postoperative morphine usage, and pain scores between the two groups.
CONCLUSION: Low-dose ketamine administration during desflurane anesthesia led to notable changes in EEG patterns and PSi values. These findings provide valuable insights into the impact of ketamine on brain activity, and offer essential information for clinical anesthesiologists.
Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
PURPOSE: A pharmaceutical composition containing Trichosanthes kirilowii maxim extract is provided to overcome anticancer drug resistance in multidrug resistant cells and to be used as an anticancer aid. CONSTITUTION: A pharmaceutical composition for inhibiting multidrug resistance contains Trichosanthes kirilowii maxim extract as an active ingredient. The extract is prepared using water, low carbon number alcohol of 1-4 carbon atoms, or a mixture solvent thereof. The multidrug resistance is multidrug resistance by P-glycoprotein. A pharmaceutical composition for anticancer aid contains 0.001-50 wt% of the extract. A sitological composition for anticancer aid contains 0.001-50 wt% of the extract as an active ingredient.
A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried, leaving keratin solid which can be shredded into fibers and further ground into powder. Addition of water to the solid produces a hydrogel. The powder or hydrogel may be useful as an absorbent material, as a therapeutic for skin, or as an excipient. The keratin materials can be incorporated into nonwoven films. Another use for the hydrogel is as a biocompatible viscoelastic filler for implant applications.
Objective:To explore the effect of surgical treatment of the pulsatile tinnitus associated with sigmoid sinus on the dominant side of reflux. Methods:The clinical data of 43 patients with reflux dominant side pulsating tinnitus admitted by the same doctor from 2017 to 2023 were retrospectively studied to observe the curative effect of surgical treatment. Operation method: The sound insulation barrier was established by repair technique of bone wall defect of sigmoid sinus with "capping method", without changing the blood flow and blood vessel wall of sigmoid sinus. Results:No surgical complications occurred in all patients. During the follow-up period of 3 months to 6.9 years, 14 patients(32.6%) were cured, 18 patients(41.9%) were significantly effective, 4 patients(9.3%) were effective, and 7 patients(16.3%) were ineffective. The difference of tinnitus grade before and after surgery was statistically significant. Conclusion:In this group of cases, the sound insulation barrier was established by "capping method" technique of repairing bone wall defect of sigmoid sinus, which effectively avoided the disturbance of hemorheology status and vascular wall, thus avoiding the risk of venous wall stenosis and thrombosis on the dominant reflux side. The surgical method was easy to master, and the curative effect was significant, which was worthy of clinical promotion.